Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2015
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms EARLY
- Sponsors Actelion Pharmaceuticals
- 03 Nov 2015 New source NCT00091715 identified and integrated.
- 02 Nov 2015 New trial record